Mesenchymal stem cell therapy for lung diseases: Oasis or mirage?

Respiration

Volumn 85, Issue 4, 2013, Pages 279-280

  Ntolios, Paschalis ^a   Janes, Sam M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN;

ANTIINFLAMMATORY ACTIVITY; EDITORIAL; EPITHELIUM CELL; HUMAN; LUNG DISEASE; LUNG FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; FEMALE; HUMANS; LUNG INJURY; MESENCHYMAL STEM CELL TRANSPLANTATION;

EID: 84876119625     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000346642     Document Type: Editorial

References (16)

1. Loebinger MR, Sage EK, Janes SM: Mesenchymal stem cells as vectors for lung disease. Proc Am Thorac Soc 2008; 5: 711-716.
2. Ciccocioppo R, Bernardo ME, Sgarella A, et al: Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011; 60: 788-798.
3. Connick P, Kolappan M, Crawley C, et al: Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-ofconcept study. Lancet Neurol 2012; 11: 150-156.
4. Duijvestein M, Vos AC, Roelofs H, et al: Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010; 59: 1662-1669.
5. Le Blanc K, Frassoni F, Ball L, et al: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-1586.
6. Wang D, Zhang H, Liang J, et al: Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years experience. Cell Transplant 2012, E-pub ahead of print.
7. Deans RJ, Moseley AB: Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000; 28: 875-884.
8. Rasmusson I, Ringdén O, Sundberg B, et al: Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76: 1208-1213.
9. Waterman RS, Tomchuck SL, Henkle SL, et al: A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 2010; 5:e10088.
10. Le Blanc K, Mougiakakos D: Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 2012; 12: 383-396.
11. Aguilar S, Scotton CJ, McNulty, et al: Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One 2009; 4:e8013.
12. McNulty K, Janes SM: Stem cells and pulmonary fibrosis: cause or cure? Proc Am Thorac Soc 2012; 9: 164-171.
13. Lim R, Milton P, Murphy SV, et al: Human mesenchymal stem cells reduce lung injury in immunocompromised mice but not in immunocompetent mice. Respiration 2013;85: 332-341.
14. Murphy S, Lim R, Dickinson H, et al: Human amnion epithelial cells prevent bleomycin-induced lung injury and preserve lung function. Cell Transplant 2011; 20: 909-923.
15. Moodley Y, Ilancheran S, Samuel C, et al: Human amnion epithelial cell transplantation abrogates lung fibrosis and augments repair. Am J Respir Crit Care Med 2010; 182: 643-651.
16. Moodley Y, Atienza D, Manuelpillai U, et al: Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Pathol 2009; 175: 303-313.